Percy H. Carter - Concepedia

Author

Percy H. Carter

Bristol-Myers Squibb (United States)ORCID

Also Known As

Carter, Percy H., Percy H Carter, Percy H. Carter

132

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Biocon (India)Harvard University Bristol-Myers Squibb (India)Massachusetts General Hospital

About

Percy H. Carter is an author at Bristol-Myers Squibb (United States) specializing in drug discovery, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	40	1.5K
2	Natural Sciences	16	23	925
3	Biochemistry	16	22	883
4	Engineering	5	5	142
5	Allergy	1	1	136

Percy H. Carter

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165 Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin, Journal of Medicinal Chemistry	2019	345
Total Synthesis of Bryostatin 2 David A. Evans, Percy H. Carter, Erick M. Carreira, Journal of the American Chemical Society Synthesis PlanMedicinal ChemistryBioorganic ChemistryBiochemistryNatural Sciences	1999	254
Discovery of 6-Fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers Scott H. Watterson, George V. De Lucca, Qing Shi, Journal of Medicinal Chemistry	2016	142
Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-α Percy H. Carter, Peggy Scherle, Jodi A. Muckelbauer, Proceedings of the National Academy of Sciences Crystal StructureImmunologyCell DeathInflammationMedicinal Chemistry	2001	136
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK) Scott H. Watterson, Qingjie Liu, Myra Beaudoin Bertrand, Journal of Medicinal Chemistry Tyrosine KinaseImmunologyQuantitative PharmacologyBiological TherapyInnate Immunity	2019	104
The Discovery of Macrocyclic XIAP Antagonists from a DNA-Programmed Chemistry Library, and Their Optimization To Give Lead Compounds with in Vivo Antitumor Activity Benjamin A. Seigal, William H. Connors, Andrew W. Fraley, Journal of Medicinal Chemistry Lead CompoundsMolecular BiologyLead IdentificationChemical BiologyPharmaceutical Chemistry	2015	85
Identification of <i>N</i>-Methyl Nicotinamide and <i>N</i>-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2) Ryan Moslin, Yanlei Zhang, Stephen T. Wrobleski, Journal of Medicinal Chemistry	2019	84
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2 Chunjian Liu, James C. Lin, Charles M. Langevine, Journal of Medicinal Chemistry	2020	76
The (1–14) Fragment of Parathyroid Hormone (PTH) Activates Intact and Amino-Terminally Truncated PTH-1 Receptors Michael D. Luck, Percy H. Carter, Thomas J. Gardella Molecular Endocrinology	1999	74
Both 5-arylidene-2-thioxodihydropyrimidine-4,6(1H,5H)-diones and 3-thioxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-ones are light-Dependent tumor necrosis factor-α antagonists Matthew E. Voss, Percy H. Carter, Andrew J. Tebben, Bioorganic & Medicinal Chemistry Letters InflammationMolecular PharmacologyMedicinal ChemistryAnti-inflammatoryAntiparasitic Agent	2003	69

Page 1